Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Taro Pharmaceuticals U.S.A., Inc.
EIR
•Taro Pharmaceuticals U.S.A., Inc.•August 27, 2018

Taro Pharmaceuticals U.S.A., Inc. – FDA EIR, Aug 27, 2018

Record Details

An FDA surveillance inspection of Taro Pharmaceuticals U.S.A., Inc., based in Hawthorne, NY, took place on August 27, 2018. The inspection was a Postmarketing Adverse Drug Experience (PADE)-initiated review, conducted under Compliance Program 7353.001, which specifically governs the reporting of adverse drug events. This regulatory framework ensures that pharmaceutical companies effectively monitor and report potential side effects and safety issues associated with their marketed products. The inspection's scope centered on Taro's systems for the surveillance, receipt, evaluation, and submission of adverse drug event data. The company, which develops and markets brand and generic prescription drugs, as well as over-the-counter products manufactured in Israel and Canada, outsources portions of its PADE responsibilities, including intake of ADEs and complaints, to a third-party contractor. During the comprehensive review of various records, including written procedures, contractor agreements, adverse drug experience case files, complaint logs, and annual reports, the FDA investigator identified no discrepancies. As a result, an FDA Form 483, Inspectional Observations, was not issued to Taro Pharmaceuticals U.S.A., Inc. This favorable outcome indicates that the firm was found to be operating in compliance with the established regulatory requirements for postmarketing adverse drug experience reporting, and no specific violations or required actions were cited from this inspection.

Company
Taro Pharmaceuticals U.S.A., Inc.
Inspection date
August 27, 2018
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Tara K. Carmody
View Company Profile

ID · 9c647068-04a2-40a8-b158-dafa0ee6a236

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Taro Pharmaceuticals U.S.A., Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.